Cardiovascular SAEs reported over @ years of follow-up were assessed in @ golimumab phase @ clinical trials of patients with rheumatoid arthritis ( GO-BEFORE , GO-FORWARD , and GO-AFTER ) , psoriatic arthritis ( GO-REVEAL ) , and ankylosing spondylitis ( GO-RAISE ) .